Clinical trials: HIV-infected
HIV-1-infection
10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
Many HIV-infected individuals mount a broad neutralizing serologic response 2-3 years after infection. Broadly neutralizing antibodies might play an important role in protection from acquisition of HIV infection because they can…
- Trial name
- NCT03875209
- Testing
- 10E8.4/iMab
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- David Ho
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Tuberculosis Infection
Micro RNA as Prediction and/or Prognostic Markers of IRIS in TB-HIV Co-infected Patients
The role of miRNAs in HIV disease is yet to be completely defined. Host miRNAs target certain HIV genes, thus can affect HIV replication and participate in viral control.
- Trial name
- miRNA (NCT03941210)
- Testing
- Detection of molecular Biomarkers
- Where
- Cambodia
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Cardiovascular Disease
A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults
HIV was once a fatal diagnosis, but due to treatment advances it is no longer a death sentence. Today, HIV-infected adults face a new challenge to their health; they are developing cardiovascular disease (CVD) earlier and more…
- Trial name
- NCT02553291
- Testing
- SystemCHANGE, Control
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
CMV
Effect of Atorvastatin on Subclinical Atherosclerosis
Statin administration is supposed to reduce subclinical atherosclerosis by decreasing LDL cholesterol levels, possibly via lipid-independent anti-inflammatory effect.
- Trial name
- NCT04101136
- Where
- Indonesia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
HIV Infections
Therapeutic Vaccination Followed by Treatment Interruption in HIV Infected Patients
The aim of this trial is to find out if immune responses to HIV can be boosted in individuals who start medicines soon after being infected.
- Trial name
- NCT00058734
- Testing
- Dendritic Cells Pulsed with HIV antigens
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Hepatitis C, Chronic
The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
The purpose of this research study is to explore what role immune cells within the gut (the sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or HCV/ HIV co-infection.
- Conditions
- HIV, Hepatitis C, Chronic, HCV Coinfection
- Trial name
- NCT01335230
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
HIV Infections, HIV Seronegativity
Carotid Artery Thickness in HIV Infected and Uninfected Adults
The intima-media thickness (IMT) test is a low cost, non-invasive way to measure the thickness of the carotid artery (the large artery in the neck).
- Conditions
- HIV Infections, HIV Seronegativity, Atherosclerosis
- Trial name
- NCT00007319
- Where
- 10 sites in United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients
Concomitant administration of recombinant human growth hormone (rhGH) may boost the expansion of immune reconstitution and broaden specific T cell responses not achievable by vaccination alone.
- Trial name
- NCT00287677
- Testing
- recombinant human Growth Hormone, Vaccination, HAART
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Germans Trias i Pujol Hospital
Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
This study will test the effectiveness of topical thalidomide in healing mouth sores in HIV infected patients. Oral (PO) thalidomide heals these sores at a dose of 200 mg per day.
- Conditions
- Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
- Trial name
- NCT00001524
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Gonorrhea, Chlamydia
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections (STIs), including…
- Conditions
- Gonorrhea, Chlamydia, Syphilis
- Trial name
- NCT03980223
- Testing
- Doxycycline Hyclate Delayed-Release 200 mg
- Where
- 3 sites in United States
- Volunteers
- 641 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and…
- Trial name
- NCT03554408
- Testing
- 10-1074-LS, 3BNC117-LS
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infection
Connect to Protect Partnerships for Youth Prevention Interventions: Phase II
This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials…
- Trial name
- NCT00103896
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 16,706 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Assessment of Cytokine Values in Serum and by RT-PCR in HIV-1 Individuals With and Without HAART
A cross-sectional study was performed on HIV-1 infected individuals with or without antiretroviral treatment. 73 HIV-1 infected individuals were divided into three groups: G1= 15 infected individuals with or without AIDS who…
- Trial name
- NCT00746473
- Where
- Brazil
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV Infections, Measles
A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group
To compare measles seroconversion rates (development of antibodies) at 13 months of age in HIV-infected and uninfected children on one of two immunization schedules: attenuated measles/mumps/rubella virus (M-M-R II) vaccine at 12…
- Trial name
- NCT00000815
- Testing
- Attenuvax, M-M-R-II
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Neonatal Infection
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal…
- Conditions
- HIV Infections, Neonatal Infection, LTBI - Latent Tuberculosis Infection, Immune Tolerance
- Trial name
- IMMUNEO (NCT03383211)
- Testing
- RNAseq
- Where
- 2 sites in Moldova
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- George Washington University
Human Immunodeficiency Virus
Improving Prognosis in HIV Infection
The primary objective of this study is to assess the safety of probiotics in cART-treated immunologic non-responder (INR) patients with chronic HIV infection.
- Trial name
- NCT02640625
- Testing
- Probiotic compound
- Where
- Norway
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Influenza
Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand
This study will assess the efficacy of a new intradermal formulation of the trivalent inactivated influenza vaccine compared to the standard intramuscular vaccine in HIV-infected men who have sex with men in Bangkok, Thailand.
- Trial name
- NCT01538940
- Testing
- Intradermal vaccine, Intramuscular vaccine
- Where
- Thailand
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Healthy, HIV
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
The proposed study is a first-in-man phase I study that aims to evaluate the safety, tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects, and its antiretroviral activity in HIV-infected…
- Trial name
- NCT02018510
- Testing
- 1 mg/kg, single dose IV administration of 3BNC117, 3 mg/kg, single dose IV administration of 3BNC117, 10 mg/kg, single dose IV administration of 3BNC117
- Where
- 4 sites in United States, Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Rockefeller University